Acumen Pharmaceuticals (ABOS) Q3 FY26 earnings call

Acumen Pharmaceuticals is nearing a critical inflection point with the anticipated top-line Phase II ALTITUDE-AD trial results for its lead Alzheimer's candidate, sabirnetug, expected in November. The study aims to validate the A-beta oligomer hypothesis with clinically meaningful endpoints. Concurrently, the company is advancing its next-generation Enhanced Brain Delivery program, leveraging insights from sabirnetug's development to refine future clinical strategies.